Earlier alignment on trial design, evidence generation and geography can help emerging biopharma companies navigate ...

Technology transfer creates plenty of documentation. Process descriptions, risk assessments, batch records, specifications, ...

Stage-appropriate development can help lean biotech teams preserve capital, manage risk and maintain momentum without closing ...

Mike Stenberg, VP, Business Development, LGM Pharma, discusses LGM's strategic expansion, lessons learned from previous ...

Agile CDMO partnerships can preserve scientific knowledge, reduce handoff risk and help programs move more smoothly from ...

Understanding a CDMOs operating model under uncertainty can help determine whether it is the right partner for the program.

How early risk identification, standardized processes and digital technologies can help sponsors streamline technology ...

For high-dose, high-concentration biologics, early alignment preserves flexibility, exposes risks before they become expensive and avoids constraints in manufacturing, clinical de ...

Brenton Saba is Vice President of Business Development at NewAtom Labs, where he leads commercial strategy and growth across North and South America. He develops strategic partnerships and works with ...

Tony Bedford is a Commercial Director, Platform Management & Innovation at Phillips Medisize and has been involved in the design and development of medical devices for over 25 years. Prior to joining ...

Biopharma companies are looking beyond available capacity to CDMO networks that can adapt across sites, scales and changing ...

This week on "The Friday Brief," whether announcing a new launch or unveiling a new identity, companies generated plenty of ...